Philly Labs Get Millions to Cure Rare Genetic Diseases

Scientists in Philadelphia are racing to turn rare genetic diseases from lifelong burdens into one-time cures.

The federal government just awarded millions to two Philadelphia labs with an ambitious challenge: get gene therapies into human trials within three years. One award went to Children's Hospital of Philadelphia, which recently treated a baby with rare genetic disorder using gene therapy. The other went to GEMMABio, founded by gene therapy pioneer Jim Wilson.

For decades, patients with rare genetic diseases faced an impossible problem. Each person's mutation is unique, meaning each would need their own custom gene therapy. That's expensive, slow, and leaves most patients without hope.

Wilson's team is flipping that approach. Working with an AI gene editing company, they're developing treatments that work for multiple patients despite their different mutations. "What we're trying to achieve in this program is to find a way to do that efficiently and do it at scale to ensure access," Wilson said.

The research focuses on two devastating conditions. Maple syrup urine disease prevents the body from breaking down parts of proteins, forcing patients onto severely restrictive diets for life. Homozygous familial hypercholesterolemia causes dangerous cholesterol buildup starting in childhood, dramatically increasing heart disease risk.

Right now, these diseases can be managed but never cured. Wilson's research aims to change that.

The team is also solving another massive challenge: how to get gene therapy into the body. Current treatments use viruses as delivery vehicles, but the immune system treats them like infections. Patients essentially get vaccinated against their own cure, making repeat doses impossible.

Wilson's solution uses tiny fat-based molecules called lipid nanoparticles instead. Think of them as microscopic packages that slip past immune defenses.

The Ripple Effect

The three-year timeline seems impossibly fast. Animal studies alone typically take over a decade before reaching human trials. But cardiologist Jaideep Patel from Johns Hopkins Medicine sees the urgency as warranted. "It's very quick, but it's certainly not impossible," he said.

For patients on current treatments, staying on medication is the biggest battle. About half quit after the first year, leaving them vulnerable again. A single lifetime dose would eliminate that problem entirely.

Preventive cardiologist Anandita Kulkarni envisions a transformed future. "You would make a diagnosis of homozygous familial hypercholesterolemia and within a single administration of this, essentially quote unquote cure the disease," she said.

Wilson acknowledges the timeline is tight but manageable. He's spent 40 years working toward this moment. The real pressure, he notes, comes from somewhere else entirely.

"The real time pressure comes from the patients living with those diseases that want a solution."